US Prostate Cancer Drug Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon.
“US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Prostate Cancer Drug Pipeline Analysis” research report:
Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon.
“US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Prostate Cancer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 11
- Preclinical: 44
- Unknown Phase: 4
- Phase 0: 1
- Phase-I: 22
- Phase-I/II: 18
- Phase-II: 53
- Phase-II/III: 1
- Phase-III:14
- Marketed: 13
1. US PROSTATE CANCER MARKET OVERVIEW
2. PROSTATE CANCER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Prostate Cancer Drug Profile in Clinical Phase
3. PROSTATE CANCER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Prostate Cancer Drug Profile in Clinical Phase
4. PROSTATE CANCER DRUG CLINICAL PHASE: UNKNOWN PHASE
4.1 Overview
4.2 Prostate Cancer Drug Profile in Clinical Phase
5. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE
5.1 Overview
5.2 Prostate Cancer Drug Profile in Clinical Phase
6. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-I
6.1 Overview
6.2 Prostate Cancer Drug Profile in Clinical Phase
7. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE I/II
7.1 Overview
7.2 Prostate Cancer Drug Profile in Clinical Phase
8. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE II
8.1 Overview
8.2 Prostate Cancer Drug Profile in Clinical Phase
9. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-II/III
9.1 Overview
9.2 Prostate Cancer Drug Profile in Clinical Phase
10. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-III
10.1 Overview
10.2 Prostate Cancer Drug Profile in Clinical Phase
11. MARKETED DRUGS
11.1 Overview
11.2 Marketed Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
2. PROSTATE CANCER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Prostate Cancer Drug Profile in Clinical Phase
3. PROSTATE CANCER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Prostate Cancer Drug Profile in Clinical Phase
4. PROSTATE CANCER DRUG CLINICAL PHASE: UNKNOWN PHASE
4.1 Overview
4.2 Prostate Cancer Drug Profile in Clinical Phase
5. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE
5.1 Overview
5.2 Prostate Cancer Drug Profile in Clinical Phase
6. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-I
6.1 Overview
6.2 Prostate Cancer Drug Profile in Clinical Phase
7. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE I/II
7.1 Overview
7.2 Prostate Cancer Drug Profile in Clinical Phase
8. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE II
8.1 Overview
8.2 Prostate Cancer Drug Profile in Clinical Phase
9. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-II/III
9.1 Overview
9.2 Prostate Cancer Drug Profile in Clinical Phase
10. PROSTATE CANCER DRUG CLINICAL PHASE: PHASE-III
10.1 Overview
10.2 Prostate Cancer Drug Profile in Clinical Phase
11. MARKETED DRUGS
11.1 Overview
11.2 Marketed Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC Code
- Designated Brand Name
